Roche (OTCQX:RHHBY) and Spark Therapeutics (NASDAQ:ONCE) have announced yet another extension of the Swiss drugmaker’s $4.3B takeover offer for the U.S. gene therapy specialist as regulatory reviews in the U.S. and Britain continue.
The offer for Spark shares now runs to Oct. 1, Roche said, adding that around 24.1% of Spark’s outstanding shares had been tendered as of the end of August.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.